Fig. 3From: The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritisCorrelation between change in biomarkers C1M, C3M, and C4M and change in SDAI scores. SDAI, Simplified Disease Activity Index. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001Back to article page